Rosemont Pharmaceuticals agrees to buy Aytu BioPharma for $2.70 a share in cash, a 51.7% premium
Aytu BioPharma (SEC 8-K) · · AI-summarised by FinFlash
Rosemont Pharmaceuticals agreed to acquire Aytu BioPharma through an all-cash tender offer at $2.70 per share, followed by a merger at the same price. The offer is a 51.7% premium to Aytu's November 13 close and 41.1% above its 30-day volume-weighted average price. Aytu's board approved the deal unanimously, and holders including Nantahala Capital, Stonepine Capital and company insiders signed tender support agreements. Closing is expected by late December 2026.
So What?
Aytu shares should trade toward the $2.70 offer; the deal marks continued consolidation among small-cap US specialty pharma companies.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.